News

The parties have agreed to licensing and other terms and assurance of protection of disputed intellectual property. Remaining terms of the settlement agreement are confidential.

The objective of the Phase IIa study is to assess hemodynamic and renal effects of CD-NP in patients with acute heart failure. In this dose escalation trial, stabilized

Mr Lordeman joins OrthoMEMS after serving as the COO of the Cleveland Clinic Foundation and Health System. Previously, Mr Lordeman spent over 20 years in healthcare leadership positions

In each study, aplindore demonstrated highly significant efficacy and was well tolerated. Neurogen believes aplindore’s dopamine partial agonist controlled release profile may be better tolerated, with fewer side

Each whole warrant will entitle the holder thereof to purchase one common share of the company at a price of $0.25 per share for a period of 36

The Angio-Seal Evolution device is designed to enable physicians to quickly and effectively seal femoral artery punctures made during minimally invasive catheter-based procedures. Effectively sealing the puncture helps

Mr Lister will serve on the board’s compensation committee and will focus on guiding the company in the commercialization of new molecular assays. Most recently, Mr Lister was

The new divisions include an in vitro diagnostics (IVD) division specifically focused on accelerating AMDL’s market launch for the AMDL-ELISA DR-70 (FDP) cancer test; a cancer therapeutics division

The technology was developed by Michael Czech, professor and chair, program in molecular medicine at the University of Massachusetts Medical School (UMMS) and an RXi founder, and Gary